CNBC’s Angelica Peebles joins ‘Fast Money’ to report on Bristol Myers Squibb’s stock rise following FDA approval of Cobenfy for treating schizophrenia in adults.
Trending
- Israel and Hamas Work on Final Details of Gaza Cease-Fire Deal, Officials Say
- Stocks making the biggest moves premarket: GS, WFC, RGTI META
- Deutsche Bank upgrades this real estate stock due to strong demand for data centers
- Citigroup (C) earnings Q4 2024
- A House at Auschwitz Opens Its Doors to a Chilling Past
- Wells Fargo WFC earnings Q4 2024
- Morgan Stanley upgrades this commercial real estate stock, sees nearly 30% upside ahead
- Mortgage demand is mixed, as interest rates hit highest level since May
Bristol Myers Squibb stock rises following FDA approval of its schizophrenia drug
